Literature DB >> 11557110

Overall survival and local recurrence of 406 completely resected stage IIIa-N2 non-small cell lung cancer patients: questionnaire survey of the Japan Clinical Oncology Group to plan for clinical trials.

Y Ichinose1, H Kato, T Koike, R Tsuchiya, T Fujisawa, N Shimizu, Y Watanabe, T Mitsudomi, M Yoshimura.   

Abstract

BACKGROUND: the group of completely resected stage IIIA-N2 non-small cell lung cancer patients (NSCLC) is considered to be heterogeneous in various aspects including survival and the recurrent pattern. In the present study, we attempted to clarify the factors which separate these patients into high and low risk groups based on the survival and local recurrence.
METHODS: a questionnaire survey on the survival and local recurrence of non-small cell lung cancer patients with pathological stage IIIA-N2 disease who underwent a complete resection from January 1992 to December 1993 was performed by the Japan Clinical Oncology Group as of July 1999. The information on the survival of 406 patients and that of local recurrence in 332 of them was available.
RESULTS: the 5-year survival of the 406 patients was 31.0%. In a univariate analysis, the age, clinical and pathological T status, number of N2 stations, pathological N1 disease, operative modality and postoperative radiotherapy were all found to be important prognostic factors. Clinical N2 disease marginally influenced the survival (P=0.07). In a multivariate analysis of these variables including clinical N2 disease, the survival was significantly worse in the case of multiple N2 stations (hazard ratio=1.741), the presence of pathological N1 disease (1.403), pathological T2 or 3 disease (1.399) and an age older than 65 (1.327). The rate of freedom from any local recurrence at the bronchial stump, or in the hilar, mediastinal or supraclavicular lymph nodes at 5 years was 64%. In a univariate analysis of the freedom from local recurrence, the clinical N status, pathological T status, pathological N1 disease and number of N2 stations were all found to be important prognostic factors. A multivariate analysis revealed the freedom from local recurrence to be adversely influenced by multiple N2 stations (hazard ratio=2.05), and the presence of either clinical N1 or 2 (1.733) disease. The 5-year survival and the rate of freedom from local recurrence at 5 years were 43 and 75% in patients with a single N2 station and 17 and 48% in those with multiple N2 stations, respectively.
CONCLUSIONS: the number of N2 stations (single vs. multiple N2 stations) was found to be a useful prognostic factor, which can separate completely resected stage IIIA-N2 patients into high and low risk groups regarding both the overall survival and local recurrence.

Entities:  

Mesh:

Year:  2001        PMID: 11557110     DOI: 10.1016/s0169-5002(01)00207-0

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  27 in total

1.  Factors affecting tumor recurrence after curative surgery for NSCLC: impacts of lymphovascular invasion on early tumor recurrence.

Authors:  Chanyeong Park; In Jae Lee; Seung Hun Jang; Jae Woong Lee
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

2.  The impact of positive nodal chain ratio on individualized multimodality therapy in non-small-cell lung cancer.

Authors:  Qinchen Cao; Baozhong Zhang; Lujun Zhao; Changli Wang; Liqun Gong; Jun Wang; Qingsong Pang; Kai Li; Weishuai Liu; Xue Li; Peng Wang; Ping Wang
Journal:  Tumour Biol       Date:  2015-01-27

Review 3.  Radiotherapy for single station N2 NSCLC.

Authors:  Jan P van Meerbeeck
Journal:  Transl Lung Cancer Res       Date:  2014-08

4.  Survival impact of node zone classification in resected pathological N2 non-small cell lung cancer.

Authors:  Tetsuro Baba; Hidetaka Uramoto; Taiji Kuwata; Yasuhiro Chikaishi; Makoto Nakagawa; Tomoko So; Takeshi Hanagiri; Fumihiro Tanaka
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-02-27

5.  Postoperative radiotherapy option based on mediastinal lymph node reclassification for patients with pN2 non-small-cell lung cancer.

Authors:  J Jin; Y Xu; X Hu; M Chen; M Fang; Q Hang; M Chen
Journal:  Curr Oncol       Date:  2020-06-01       Impact factor: 3.677

6.  Chemically modified heparin inhibits the in vitro adhesion of nonsmall cell lung cancer cells to P-selectin.

Authors:  Yanguang Gao; Min Wei; Sheng Zheng; Xueqing Ba; Shui Hao; Xianlu Zeng
Journal:  J Cancer Res Clin Oncol       Date:  2005-12-06       Impact factor: 4.553

Review 7.  Role of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on new data.

Authors:  Cécile Le Péchoux
Journal:  Oncologist       Date:  2011-03-04

8.  Impact of main bronchial lymph node involvement in pathological T1-2N1M0 non-small-cell lung cancer: multi-institutional survey by the Japan National Hospital Study Group for Lung Cancer.

Authors:  Hajime Maeda; Shimao Fukai; Akihide Matsumura; Osamu Kawashima; Takehiro Watanabe; Takeshi Yamanda; Kan Okabayashi; Yuka Fujita; Atsuhisa Tamura; Masaaki Kawahara
Journal:  Gen Thorac Cardiovasc Surg       Date:  2009-11-12

9.  Morphometric analysis of regional lymph nodes in surgically resected non-small cell lung cancer.

Authors:  Hajimu Gotoh; Naoki Kanomata; Masahiro Yoshimura; Yoshiharu Ohno; Takuya Moriya; Chiho Ohbayashi
Journal:  Med Mol Morphol       Date:  2009-09-26       Impact factor: 2.309

10.  Independent predictive value of the overall number of metastatic N1 and N2 stations in lung cancer.

Authors:  Kazuhiro Ueda; Yoshikazu Kaneda; Hisashi Sakano; Toshiki Tanaka; Masatarou Hayashi; Tao-Sheng Li; Kimikazu Hamano
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2003-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.